1
|
Royet C, Diot S, Onofre M, Lecki L, Pastore M, Reynes C, Lorcy F, Lacheretzszablewski V, Serre I, Morris MC. Multiplexed Profiling of CDK Kinase Activities in Tumor Biopsies with Fluorescent Peptide Biosensors. ACS Sens 2024; 9:2964-2978. [PMID: 38863434 DOI: 10.1021/acssensors.4c00139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2024]
Abstract
Detection of disease biomarkers constitutes a major challenge for the development of personalized and predictive diagnostics as well as companion assays. Protein kinases (PKs) involved in the coordination of cell cycle progression and proliferation that are hyperactivated in human cancers constitute attractive pharmacological targets and relevant biomarkers. Although it is relatively straightforward to assess the relative abundance of PKs in a biological sample, there is not always a direct correlation with enzymatic activity, which is regulated by several posttranslational mechanisms. Studies of relative abundance therefore convey limited information, and the lack of selective, sensitive, and standardized tools together with the inherent complexity of biological samples makes it difficult to quantify PK activities in physio-pathological tissues. To address this challenge, we have developed a toolbox of fluorescent biosensors that report on CDK activities in a sensitive, selective, dose-dependent, and quantitative fashion, which we have implemented to profile CDK activity signatures in cancer cell lines and biopsies from human tumors. In this study, we report on a standardized and calibrated biosensing approach to quantify CDK1,2,4, and 6 activities simultaneously through a combination of four different biosensors in a panel of 40 lung adenocarcinoma and 40 follicular lymphoma samples. CDK activity profiling highlighted two major patterns which were further correlated with age, sex of patients, tumor size, grade, and genetic and immunohistochemical features of the biopsies. Multiplex CDKACT biosensing technology provides new and complementary information relative to current genetic and immunohistochemical characterization of tumor biopsies, which will be useful for diagnostic purposes, potentially guiding therapeutic decision. These fluorescent peptide biosensors offer promise for personalized diagnostics based on kinase activity profiling.
Collapse
Affiliation(s)
- Chloé Royet
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Montpellier University, 1919 Route de Mende, 34293 Montpellier, France
| | - Sébastien Diot
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Montpellier University, 1919 Route de Mende, 34293 Montpellier, France
| | - Mélanie Onofre
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Montpellier University, 1919 Route de Mende, 34293 Montpellier, France
| | - Lennard Lecki
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Montpellier University, 1919 Route de Mende, 34293 Montpellier, France
| | - Manuela Pastore
- StatABio Facility─Biocampus, UAR 3426 CNRS─US 09 INSERM, Montpellier University, 141 rue de la Cardonille, 34094 Montpellier Cedex 05, France
| | - Christelle Reynes
- StatABio Facility─Biocampus, UAR 3426 CNRS─US 09 INSERM, Montpellier University, 141 rue de la Cardonille, 34094 Montpellier Cedex 05, France
| | - Frederique Lorcy
- University Hospital Centre Montpellier, 80 Av. Augustin Fliche, 34295 Montpellier, France
| | | | - Isabelle Serre
- University Hospital Centre Montpellier, 80 Av. Augustin Fliche, 34295 Montpellier, France
| | - May C Morris
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Montpellier University, 1919 Route de Mende, 34293 Montpellier, France
| |
Collapse
|
2
|
Chatzilakou E, Hu Y, Jiang N, Yetisen AK. Biosensors for melanoma skin cancer diagnostics. Biosens Bioelectron 2024; 250:116045. [PMID: 38301546 DOI: 10.1016/j.bios.2024.116045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Revised: 01/10/2024] [Accepted: 01/15/2024] [Indexed: 02/03/2024]
Abstract
Skin cancer is a critical global public health concern, with melanoma being the deadliest variant, correlated to 80% of skin cancer-related deaths and a remarkable propensity to metastasize. Despite notable progress in skin cancer prevention and diagnosis, the limitations of existing methods accentuate the demand for precise diagnostic tools. Biosensors have emerged as valuable clinical tools, enabling rapid and reliable point-of-care (POC) testing of skin cancer. This review offers insights into skin cancer development, highlights essential cutaneous melanoma biomarkers, and assesses the current landscape of biosensing technologies for diagnosis. The comprehensive analysis in this review underscores the transformative potential of biosensors in revolutionizing melanoma skin cancer diagnosis, emphasizing their critical role in advancing patient outcomes and healthcare efficiency. The increasing availability of these approaches supports direct diagnosis and aims to reduce the reliance on biopsies, enhancing POC diagnosis. Recent advancements in biosensors for skin cancer diagnosis hold great promise, with their integration into healthcare expected to enhance early detection accuracy and reliability, thereby mitigating socioeconomic disparities.
Collapse
Affiliation(s)
- Eleni Chatzilakou
- Department of Chemical Engineering, Imperial College London, South Kensington, London, SW7 2BU, UK
| | - Yubing Hu
- Department of Chemical Engineering, Imperial College London, South Kensington, London, SW7 2BU, UK.
| | - Nan Jiang
- West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, 610041, China; JinFeng Laboratory, Chongqing, 401329, China.
| | - Ali K Yetisen
- Department of Chemical Engineering, Imperial College London, South Kensington, London, SW7 2BU, UK.
| |
Collapse
|
3
|
Gao Y, Yang R, Lou K, Dang Y, Dong Y, He Y, Huang W, Chen M, Zhang G. In vivo visualization of fluorescence reflecting CDK4 activity in a breast cancer mouse model. MedComm (Beijing) 2022; 3:e136. [PMID: 35711853 PMCID: PMC9187519 DOI: 10.1002/mco2.136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Revised: 03/21/2022] [Accepted: 03/23/2022] [Indexed: 11/06/2022] Open
Abstract
The CDK4/6-Rb axis is a crucial target of cancer therapy and several selective inhibitors of it have been approved for clinical application. However, current therapeutic efficacy evaluation mostly relies on anatomical imaging, which cannot directly reflect changes in drug targets, leading to a delay in the selection of optimal treatment. In this study, we constructed a novel fluorescent probe, CPP30-Lipo/CDKACT4, for real-time monitoring of CDK4 activity and the therapeutic efficacy of its inhibitor in HR+/HER2- breast cancer. CPP30-Lipo/CDKACT4 exhibited good optical stability and targetability. The signal of the probe in living cells decreased after CDK4 knockdown or palbociclib treatment. Moreover, the fluorescence intensity of the tumors after 7 days of palbociclib treatment was significantly lower than that before treatment, while no significant change in tumor diameter was observed under magnetic resonance imaging. Overall, we developed an innovative fluorescent probe that can monitor CDK4 activity and the early therapeutic response to CDK4 inhibitors in living cells and in vivo. It may provide a new strategy for evaluating antitumor therapeutic efficacy in a clinical context and for drug development.
Collapse
Affiliation(s)
- Yi‐Yang Gao
- Department of Breast and Thyroid SurgeryXiang'an Hospital of Xiamen University, School of Medicine, Xiamen UniversityXiamenChina
- Fujian Key Laboratory of Precision Diagnosis and Treatment in Breast CancerXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Xiamen Key Laboratory of Endocrine‐Related Cancer Precision MedicineXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Central LaboratoryXiang'an Hospital of Xiamen University, School of Medicine, Xiamen UniversityXiamenChina
| | - Rui‐Qin Yang
- Department of Breast and Thyroid SurgeryXiang'an Hospital of Xiamen University, School of Medicine, Xiamen UniversityXiamenChina
- Fujian Key Laboratory of Precision Diagnosis and Treatment in Breast CancerXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Xiamen Key Laboratory of Endocrine‐Related Cancer Precision MedicineXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Central LaboratoryXiang'an Hospital of Xiamen University, School of Medicine, Xiamen UniversityXiamenChina
| | - Kang‐Liang Lou
- Department of Breast and Thyroid SurgeryXiang'an Hospital of Xiamen University, School of Medicine, Xiamen UniversityXiamenChina
- Fujian Key Laboratory of Precision Diagnosis and Treatment in Breast CancerXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Xiamen Key Laboratory of Endocrine‐Related Cancer Precision MedicineXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Central LaboratoryXiang'an Hospital of Xiamen University, School of Medicine, Xiamen UniversityXiamenChina
| | - Yong‐Ying Dang
- Department of Breast and Thyroid SurgeryXiang'an Hospital of Xiamen University, School of Medicine, Xiamen UniversityXiamenChina
- Fujian Key Laboratory of Precision Diagnosis and Treatment in Breast CancerXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Xiamen Key Laboratory of Endocrine‐Related Cancer Precision MedicineXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Central LaboratoryXiang'an Hospital of Xiamen University, School of Medicine, Xiamen UniversityXiamenChina
| | - Yuan‐Yuan Dong
- Department of Breast and Thyroid SurgeryXiang'an Hospital of Xiamen University, School of Medicine, Xiamen UniversityXiamenChina
- Fujian Key Laboratory of Precision Diagnosis and Treatment in Breast CancerXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Xiamen Key Laboratory of Endocrine‐Related Cancer Precision MedicineXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Central LaboratoryXiang'an Hospital of Xiamen University, School of Medicine, Xiamen UniversityXiamenChina
| | - Yue‐Yang He
- Department of Breast and Thyroid SurgeryXiang'an Hospital of Xiamen University, School of Medicine, Xiamen UniversityXiamenChina
- Fujian Key Laboratory of Precision Diagnosis and Treatment in Breast CancerXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Xiamen Key Laboratory of Endocrine‐Related Cancer Precision MedicineXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Central LaboratoryXiang'an Hospital of Xiamen University, School of Medicine, Xiamen UniversityXiamenChina
| | - Wen‐He Huang
- Department of Breast and Thyroid SurgeryXiang'an Hospital of Xiamen University, School of Medicine, Xiamen UniversityXiamenChina
- Fujian Key Laboratory of Precision Diagnosis and Treatment in Breast CancerXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Xiamen Key Laboratory of Endocrine‐Related Cancer Precision MedicineXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Xiamen Research Center of Clinical Medicine in Breast and Thyroid CancersXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
| | - Min Chen
- Xiamen Key Laboratory of Endocrine‐Related Cancer Precision MedicineXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Central LaboratoryXiang'an Hospital of Xiamen University, School of Medicine, Xiamen UniversityXiamenChina
- Cancer Research Center of Xiamen UniversitySchool of Medicine, Xiamen UniversityXiamenChina
| | - Guo‐Jun Zhang
- Department of Breast and Thyroid SurgeryXiang'an Hospital of Xiamen University, School of Medicine, Xiamen UniversityXiamenChina
- Fujian Key Laboratory of Precision Diagnosis and Treatment in Breast CancerXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Xiamen Key Laboratory of Endocrine‐Related Cancer Precision MedicineXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Xiamen Research Center of Clinical Medicine in Breast and Thyroid CancersXiang'an Hospital of Xiamen University, Xiamen UniversityXiamenChina
- Cancer Research Center of Xiamen UniversitySchool of Medicine, Xiamen UniversityXiamenChina
| |
Collapse
|
4
|
Hu J, Li G. Recent Progress in Fluorescent Chemosensors for Protein Kinases. Chem Asian J 2022; 17:e202200182. [PMID: 35486328 DOI: 10.1002/asia.202200182] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Revised: 04/21/2022] [Indexed: 11/10/2022]
Abstract
Protein kinases are involved in almost all biological activities. The activities of different kinases reflect the normal or abnormal status of the human body. Therefore, detecting the activities of different kinases is important for disease diagnosis and drug discovery. Fluorescent probes offer opportunities for studying kinase behaviors at different times and spatial locations. In this review, we summarize different kinds of fluorescent chemosensors that have been used to detect the activities of many different kinases.
Collapse
Affiliation(s)
- Jun Hu
- Fujian Agriculture and Forestry University, College of Life Sciences, No.15 Shangxiadian Road, Cangshan District, 350002, Fuzhou, CHINA
| | - Gao Li
- Minjiang University, College of Material and Chemical Engineering, CHINA
| |
Collapse
|
5
|
Morris MC. A Toolbox of Fluorescent Peptide Biosensors to Highlight Protein Kinases in Complex Samples : focus on cyclin‐dependent kinases. European J Org Chem 2022. [DOI: 10.1002/ejoc.202200120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- May Catherine Morris
- IBMM-UMR5247 Peptide & Proteins Faculté de Pharmacie,15 Av. Charles Flahault 34093 Montpellier FRANCE
| |
Collapse
|
6
|
Shining Light on Protein Kinase Biomarkers with Fluorescent Peptide Biosensors. Life (Basel) 2022; 12:life12040516. [PMID: 35455007 PMCID: PMC9026840 DOI: 10.3390/life12040516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Revised: 03/21/2022] [Accepted: 03/28/2022] [Indexed: 11/23/2022] Open
Abstract
Protein kinases (PKs) are established gameplayers in biological signalling pathways, and a large body of evidence points to their dysregulation in diseases, in particular cancer, where rewiring of PK networks occurs frequently. Fluorescent biosensors constitute attractive tools for probing biomolecules and monitoring dynamic processes in complex samples. A wide variety of genetically encoded and synthetic biosensors have been tailored to report on PK activities over the last decade, enabling interrogation of their function and insight into their behaviour in physiopathological settings. These optical tools can further be used to highlight enzymatic alterations associated with the disease, thereby providing precious functional information which cannot be obtained through conventional genetic, transcriptomic or proteomic approaches. This review focuses on fluorescent peptide biosensors, recent developments and strategies that make them attractive tools to profile PK activities for biomedical and diagnostic purposes, as well as insights into the challenges and opportunities brought by this unique toolbox of chemical probes.
Collapse
|
7
|
Abstract
Melanoma is a relentless type of skin cancer which involves myriad signaling pathways which regulate many cellular processes. This makes melanoma difficult to treat, especially when identified late. At present, therapeutics include chemotherapy, surgical resection, biochemotherapy, immunotherapy, photodynamic and targeted approaches. These interventions are usually administered as either a single-drug or in combination, based on tumor location, stage, and patients' overall health condition. However, treatment efficacy generally decreases as patients develop treatment resistance. Genetic profiling of melanocytes and the discovery of novel molecular factors involved in the pathogenesis of melanoma have helped to identify new therapeutic targets. In this literature review, we examine several newly approved therapies, and briefly describe several therapies being assessed for melanoma. The goal is to provide a comprehensive overview of recent developments and to consider future directions in the field of melanoma.
Collapse
Affiliation(s)
- Pavan Kumar Dhanyamraju
- Department of Pediatrics and Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
- Pavan Kumar Dhanyamraju, Department of Pediatrics and Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA17033, USA. Tel: +1-6096474712, E-mail:
| | - Trupti N. Patel
- School of Biosciences and Technology, Vellore Institute of Technology, Vellore Campus, Vellore, Tamil Nadu 632014, India
| |
Collapse
|
8
|
Pellerano M, Morris MC. Fluorescent Peptide Biosensors for Probing CDK Kinase Activity in Cell Extracts. Methods Mol Biol 2021; 2329:39-50. [PMID: 34085214 DOI: 10.1007/978-1-0716-1538-6_4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/09/2023]
Abstract
Fluorescent biosensors can report on the relative abundance, activity, or conformation of biomolecules and analytes through changes in fluorescence emission. A wide variety of genetically-encoded and synthetic biosensors have been developed to monitor protein kinase activity. We have focused on the design, engineering and characterization of fluorescent peptide biosensors of cyclin-dependent kinases (CDKs) that constitute attractive cancer biomarkers and pharmacological targets. In this chapter, we describe the CDKACT fluorescent peptide biosensor technology and its application to assess the relative kinase activity of CDKs in vitro, either using recombinant proteins or cell extracts as a more complex source of kinase. This technology offers a straightforward means of comparing CDK activity in different cell lines and evaluating the specific impact of treatments intended to target kinase activity in a physiologically relevant environment.
Collapse
Affiliation(s)
- Morgan Pellerano
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Faculté de Pharmacie, Université de Montpellier, Montpellier, France
| | - May C Morris
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Faculté de Pharmacie, Université de Montpellier, Montpellier, France.
| |
Collapse
|
9
|
Tîlmaciu CM, Dinesh B, Pellerano M, Diot S, Guidetti M, Vollaire J, Bianco A, Ménard-Moyon C, Josserand V, Morris MC. Nanobiosensor Reports on CDK1 Kinase Activity in Tumor Xenografts in Mice. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2021; 17:e2007177. [PMID: 33502119 DOI: 10.1002/smll.202007177] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/14/2020] [Revised: 12/25/2020] [Indexed: 06/12/2023]
Abstract
Probing the dynamics and quantifying the activities of intracellular protein kinases that coordinate cell growth and division and constitute biomarkers and pharmacological targets in hyperproliferative and pathological disorders remain a challenging task. Here engineering and characterization of a nanobiosensor of the mitotic kinase CDK1, through multifunctionalization of carbon nanotubes with a CDK1-specific fluorescent peptide reporter, are described. This original reporter of CDK1 activity combines the sensitivity of a fluorescent biosensor with the unique physico-chemical and biological properties of nanotubes for multifunctionalization and efficient intracellular penetration. The functional versatility of this nanobiosensor enables implementation to quantify CDK1 activity in a sensitive and dose-dependent fashion in complex biological environments in vitro, to monitor endogenous kinase in living cells and directly within tumor xenografts in mice by fluorescence imaging, thanks to a ratiometric quantification strategy accounting for response relative to concentration in space and in time.
Collapse
Affiliation(s)
- Carmen Mihaela Tîlmaciu
- Institut des Biomolécules Max Mousseron-CNRS, UMR5247, Université de Montpellier, Montpellier, 34093, France
| | - Bhimareddy Dinesh
- CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg, ISIS, Strasbourg, 67000, France
| | - Morgan Pellerano
- Institut des Biomolécules Max Mousseron-CNRS, UMR5247, Université de Montpellier, Montpellier, 34093, France
| | - Sebastien Diot
- Institut des Biomolécules Max Mousseron-CNRS, UMR5247, Université de Montpellier, Montpellier, 34093, France
| | - Mélanie Guidetti
- Institut pour l'Avancée des Biosciences, INSERM U1209, CNRS UMR-5309, Université Grenoble Alpes, Grenoble, 38000, France
| | - Julien Vollaire
- Institut pour l'Avancée des Biosciences, INSERM U1209, CNRS UMR-5309, Université Grenoble Alpes, Grenoble, 38000, France
| | - Alberto Bianco
- CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg, ISIS, Strasbourg, 67000, France
| | - Cécilia Ménard-Moyon
- CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg, ISIS, Strasbourg, 67000, France
| | - Véronique Josserand
- Institut pour l'Avancée des Biosciences, INSERM U1209, CNRS UMR-5309, Université Grenoble Alpes, Grenoble, 38000, France
| | - May C Morris
- Institut des Biomolécules Max Mousseron-CNRS, UMR5247, Université de Montpellier, Montpellier, 34093, France
| |
Collapse
|
10
|
Soamalala J, Diot S, Pellerano M, Blanquart C, Galibert M, Jullian M, Puget K, Morris MC. Fluorescent Peptide Biosensor for Probing CDK6 Kinase Activity in Lung Cancer Cell Extracts. Chembiochem 2020; 22:1065-1071. [PMID: 33112024 DOI: 10.1002/cbic.202000677] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Revised: 10/26/2020] [Indexed: 11/05/2022]
Abstract
CDK6 kinase regulates cell-cycle progression in G1, together with CDK4, but has cell-, tissue- and developmentally distinct functions associated with transcription, angiogenesis and metabolism. Although CDK6 makes an attractive cancer biomarker and target, there are no means of assessing its activity in a complex environment. In this study, we describe the design, engineering and characterisation of a fluorescent peptide biosensor derived from 6-phosphofructokinase that reports on CDK6 kinase activity through sensitive changes in fluorescence intensity. This biosensor can report on CDK6 activity in a dose-dependent fashion, thereby enabling quantification of differences in kinase activity in complex and physiologically relevant environments. Further implementation of this biosensor in different lung and melanoma cell lines, as well as in mesothelioma cell lines derived from patients together with a CDK4 biosensor highlighted differences in kinase activity between CDK6 and CDK4 kinase. This work demonstrates the utility of these selective tools for monitoring two closely related kinases comparatively and simultaneously in the same samples, thereby offering attractive perspectives for diagnostic and therapeutic purposes.
Collapse
Affiliation(s)
- Jessica Soamalala
- Institut des Biomolécules Max Mousseron-IBMM-UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093, Montpellier, France
| | - Sebastien Diot
- Institut des Biomolécules Max Mousseron-IBMM-UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093, Montpellier, France
| | - Morgan Pellerano
- Institut des Biomolécules Max Mousseron-IBMM-UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093, Montpellier, France
| | | | | | | | | | - May C Morris
- Institut des Biomolécules Max Mousseron-IBMM-UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093, Montpellier, France
| |
Collapse
|
11
|
Peyressatre M, Laure A, Pellerano M, Boukhaddaoui H, Soussi I, Morris MC. Fluorescent Biosensor of CDK5 Kinase Activity in Glioblastoma Cell Extracts and Living Cells. Biotechnol J 2020; 15:e1900474. [DOI: 10.1002/biot.201900474] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2019] [Revised: 04/13/2020] [Indexed: 12/26/2022]
Affiliation(s)
- Marion Peyressatre
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier Faculté de Pharmacie 15, Av. Charles Flahault Montpellier 34093 France
| | - Arthur Laure
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier Faculté de Pharmacie 15, Av. Charles Flahault Montpellier 34093 France
| | - Morgan Pellerano
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier Faculté de Pharmacie 15, Av. Charles Flahault Montpellier 34093 France
| | - Hassan Boukhaddaoui
- Plateau Imagerie Cellulaire MRI‐INM INM‐INSERM U 1051, Hôpital Saint Eloi 80 rue Augustin Fliche Montpellier 34091 France
| | - Ines Soussi
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier Faculté de Pharmacie 15, Av. Charles Flahault Montpellier 34093 France
| | - May C. Morris
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier Faculté de Pharmacie 15, Av. Charles Flahault Montpellier 34093 France
| |
Collapse
|
12
|
Bouclier C, Simon M, Laconde G, Pellerano M, Diot S, Lantuejoul S, Busser B, Vanwonterghem L, Vollaire J, Josserand V, Legrand B, Coll JL, Amblard M, Hurbin A, Morris MC. Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth. Am J Cancer Res 2020; 10:2008-2028. [PMID: 32104498 PMCID: PMC7019173 DOI: 10.7150/thno.40971] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Accepted: 11/19/2019] [Indexed: 12/25/2022] Open
Abstract
CDK4/cyclin D kinase constitutes an attractive pharmacological target for development of anticancer therapeutics, in particular in KRAS-mutant lung cancer patients, who have a poor prognosis and no targeted therapy available yet. Although several ATP-competitive inhibitors of CDK4 have been developed for anticancer therapeutics, they suffer from limited specificity and efficacy. Methods: As an alternative to ATP-competitive inhibitors we have designed a stapled peptide to target the main interface between CDK4 and cyclin D, and have characterized its physico-chemical properties and affinity to bind cyclin D1. Results: We have validated a positive correlation between CDK4/cyclin D level and KRAS mutation in lung cancer patients. The stapled peptide enters cells rapidly and efficiently, and inhibits CDK4 kinase activity and proliferation in lung cancer cells. Its intrapulmonary administration in mice enables its retention in orthotopic lung tumours and complete inhibition of their growth when co-administered with Abemaciclib. Conclusion: The stapled peptide targeting the main interface between CDK4 and cyclin D provides promising therapeutic perspectives for patients with lung cancer.
Collapse
|
13
|
Howells O, Rajendran N, Mcintyre S, Amini-Asl S, Henri P, Liu Y, Guy O, Cass AEG, Morris MC, Sharma S. Microneedle Array-Based Platforms for Future Theranostic Applications. Chembiochem 2019; 20:2198-2202. [PMID: 30897259 DOI: 10.1002/cbic.201900112] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Indexed: 11/06/2022]
Abstract
Theranostics involves finding the biomarkers of a disease, fighting them through site specific drug delivery and following them for prognosis of the disease. Microneedle array technology has been used for drug delivery and extended for continuous monitoring of analytes present in the skin compartment. We envisage the use of microneedle arrays for future theranostic applications. The potential of combining microneedle array-based drug delivery and diagnostics as part of closed-loop control system for the management of diseases and delivery of precision drugs in individual patients is reported in this paper.
Collapse
Affiliation(s)
- Olivia Howells
- College of Engineering, Swansea University, Fabian Way, Crymlyn Burrows, Bay Campus, Swansea, SA1 8EN, UK
| | - Natasha Rajendran
- College of Engineering, Swansea University, Fabian Way, Crymlyn Burrows, Bay Campus, Swansea, SA1 8EN, UK
| | - Sarah Mcintyre
- College of Engineering, Swansea University, Fabian Way, Crymlyn Burrows, Bay Campus, Swansea, SA1 8EN, UK
| | - Sara Amini-Asl
- College of Engineering, Swansea University, Fabian Way, Crymlyn Burrows, Bay Campus, Swansea, SA1 8EN, UK
| | - Pauline Henri
- Institut des Biomolécules Max Mousseron, UMR 5247, Université de Montpellier, Faculté de Pharmacie, 34093, Montpellier, France
| | - Yufei Liu
- Laboratory of Optoelectronic Technology and Systems, Ministry of Education, Centre for Intelligent Sensing Technology, College of Optoelectronic Engineering, Chongqing University, Chongqing, 400044, P. R China
| | - Owen Guy
- College of Engineering, Swansea University, Fabian Way, Crymlyn Burrows, Bay Campus, Swansea, SA1 8EN, UK.,Department of Chemistry, Swansea University, Singleton Campus, Swansea, SA2 8EN, UK
| | - Anthony E G Cass
- Department of Chemistry and Institute of Biomedical Engineering, Imperial College London, Exhibition Road, London, SW7 2AZ, UK
| | - May C Morris
- Institut des Biomolécules Max Mousseron, UMR 5247, Université de Montpellier, Faculté de Pharmacie, 34093, Montpellier, France
| | - Sanjiv Sharma
- College of Engineering, Swansea University, Fabian Way, Crymlyn Burrows, Bay Campus, Swansea, SA1 8EN, UK
| |
Collapse
|
14
|
Henri P, Prevel C, Pellerano M, Lacotte J, Stoebner PE, Morris MC, Meunier L. Psoriatic epidermis is associated with upregulation of CDK2 and inhibition of CDK4 activity. Br J Dermatol 2019; 182:678-689. [PMID: 31145809 DOI: 10.1111/bjd.18178] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/27/2019] [Indexed: 01/10/2023]
Abstract
BACKGROUND The cyclin-dependent kinases (CDKs) CDK2 and CDK4 are involved in regulation of cell-cycle progression, and psoriasis is characterized by hyperproliferation of basal epidermal cells. CDK inhibitory proteins (CKIs) such as p16INK 4A (p16) bind CDK4/6 kinases and prevent their interaction with D-type cyclins. CKIs such as p21Cip1 (p21) and p27Kip1 (p27) associate with CDK-cyclin complexes and prevent their activation. OBJECTIVES To gain insight into the molecular implication of CDK2 and CDK4 kinases in psoriasis, we sought to characterize expression of these kinases and associated cyclins, as well as of CKIs, and addressed the status of CDK2 and CDK4 activity in human psoriatic epidermis. METHODS A cohort of 24 patients with psoriasis participated in the study. Biopsies were removed from a chronic plaque and from nonlesional skin. CDK2, CDK4, cyclin D1, cyclin E and CKI protein expression was assessed by immunoblotting, immunohistochemistry and immunofluorescence. CDK4 and CDK2 mRNA expression was determined by real-time polymerase chain reaction. Specific kinase activities of CDK2 and CDK4 were evaluated using fluorescent peptide biosensors. RESULTS CDK2-cyclin E expression and activity were significantly increased in psoriatic epidermis compared with uninvolved adjacent skin. In contrast, CDK4-cyclin D1 activity was inhibited, although its expression was increased in psoriatic epidermis and its transcription slightly inhibited. p27 expression was reduced, while p16 and p21 expression was induced in psoriatic epidermis. CONCLUSIONS Epidermal CDK2 activity is increased in psoriatic epidermis while CDK4 activity is completely inhibited. These alterations are not associated with changes in CDK transcription and instead involve post-translational control mediated by decreased expression of p27 and p16 overexpression, respectively. What's already known about this topic? Cyclin-dependent kinases (CDKs) are involved in cell-cycle progression. The levels of cyclin partners and CDK inhibitors regulate their activity. Psoriasis is a chronic T-cell-driven inflammatory skin disease characterized by hyperproliferation of basal epidermal cells. What does this study add? Thanks to fluorescent peptide biosensors, this study demonstrates that epidermal CDK2 activity is increased in psoriatic epidermis while CDK4 activity is completely inhibited. These alterations involve post-translational control mediated by decreased expression of p27, and p16 overexpression, respectively. What is the translational message? CDK2 and CDK4 are involved in regulation of cell-cycle progression, and psoriasis is characterized by hyperproliferation of basal epidermal cells. Epidermal CDK2 activity is increased in psoriatic epidermis while CDK4 activity is completely inhibited. These alterations are not associated with changes in CDK transcription and instead involve post-translational control mediated by decreased expression of p27 and p16 overexpression, respectively. Pharmacological modulation of CDK2 and CDK4 may constitute a promising therapeutic strategy.
Collapse
Affiliation(s)
- P Henri
- Institute of Biomolecules Max Mousseron (IBMM), University of Montpellier, UMR CNRS 5247, Montpellier, France
| | - C Prevel
- Institute of Biomolecules Max Mousseron (IBMM), University of Montpellier, UMR CNRS 5247, Montpellier, France
| | - M Pellerano
- Institute of Biomolecules Max Mousseron (IBMM), University of Montpellier, UMR CNRS 5247, Montpellier, France
| | - J Lacotte
- Department of Dermatology, Caremeau University Hospital, Nîmes, France
| | - P E Stoebner
- Institute of Biomolecules Max Mousseron (IBMM), University of Montpellier, UMR CNRS 5247, Montpellier, France.,Department of Dermatology, Caremeau University Hospital, Nîmes, France
| | - M C Morris
- Institute of Biomolecules Max Mousseron (IBMM), University of Montpellier, UMR CNRS 5247, Montpellier, France
| | - L Meunier
- Institute of Biomolecules Max Mousseron (IBMM), University of Montpellier, UMR CNRS 5247, Montpellier, France.,Department of Dermatology, Caremeau University Hospital, Nîmes, France
| |
Collapse
|
15
|
|
16
|
Abstract
Melanoma represents the most aggressive and the deadliest form of skin cancer. Current therapeutic approaches include surgical resection, chemotherapy, photodynamic therapy, immunotherapy, biochemotherapy, and targeted therapy. The therapeutic strategy can include single agents or combined therapies, depending on the patient’s health, stage, and location of the tumor. The efficiency of these treatments can be decreased due to the development of diverse resistance mechanisms. New therapeutic targets have emerged from studies of the genetic profile of melanocytes and from the identification of molecular factors involved in the pathogenesis of the malignant transformation. In this review, we aim to survey therapies approved and under evaluation for melanoma treatment and relevant research on the molecular mechanisms underlying melanomagenesis.
Collapse
Affiliation(s)
- Beatriz Domingues
- Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal.,Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.,Faculty of Sciences, University of Porto, Porto, Portugal
| | - José Manuel Lopes
- Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal.,Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.,Department of Pathology, Hospital S João, Porto, Portugal.,Department of Pathology, Medical Faculty, University of Porto, Porto, Portugal
| | - Paula Soares
- Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal.,Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.,Department of Pathology, Medical Faculty, University of Porto, Porto, Portugal
| | - Helena Pópulo
- Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal.,Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
| |
Collapse
|
17
|
González-Vera JA, Bouzada D, Bouclier C, Eugenio Vázquez M, Morris MC. Lanthanide-based peptide biosensor to monitor CDK4/cyclin D kinase activity. Chem Commun (Camb) 2018; 53:6109-6112. [PMID: 28530267 DOI: 10.1039/c6cc09948c] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
We describe a lanthanide biosensor that responds to CDK4 kinase activity in melanoma cell extracts through a significant and dose dependent increase in luminescence, thanks to sensitization of a DOTA[Tb3+] complex incorporated into a CDK4 substrate peptide by a unique tryptophan residue in an adjacent phosphoaminoacid binding moiety.
Collapse
Affiliation(s)
- Juan A González-Vera
- Institut des Biomolécules Max Mousseron, CNRS, IBMM-UMR 5247, Université de Montpellier, 15 Av. Charles Flahault, 34093 Montpellier, France.
| | | | | | | | | |
Collapse
|
18
|
Flexible nanohybrid microelectrode based on carbon fiber wrapped by gold nanoparticles decorated nitrogen doped carbon nanotube arrays: In situ electrochemical detection in live cancer cells. Biosens Bioelectron 2018; 100:453-461. [DOI: 10.1016/j.bios.2017.09.038] [Citation(s) in RCA: 64] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Accepted: 09/20/2017] [Indexed: 11/23/2022]
|